Year: 2025
Type: article
Abstract: iMDSCs, which showed higher immunosuppressive capacity than CD14 -MDSCs, will be required.However, an attempt to increase the CD14 + cell yield by adding GM-CSF between day 12 and day 19 was not successful.Furthermore, in the investigated model, the homing efficiency to the intestine, the major target organ of therapy-refractory GVHD, was lower than to the lungs and liver.Transduction with an E-cadherin chimeric antigen receptor (CAR) did not change the in vivo life span of iMDSCs or result in an outcome benefit, unlike previous studies with E-cadherin CAR-transduced MSCs. 10 The clinical development of iMDSCs will require optimization of both cell dose and treatment schedule.Moreover, even though the current study demonstrated that highdose dexamethasone did not alter iMDSC phenotype or in vitro suppressive function, the impact of other GVHD therapies on iMDSC activity remains to be elucidated.In summary, the study by Ma et al provides a promising and scalable platform for generating iPSC-derived MDSCs with preserved immunosuppressive function in inflammatory environments, offering a viable path toward further exploration of iMDSC efficacy in GVHD.
Source: Blood
Authors: Francesca Gay, Mattia D’Agostino
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4415478383